When: Confirmed 50 SMA touch

Then: ADD SECOND HALF at $1,115-$1,125

HOLD existing position; do not add above 1150; wait for either confirmed breakout above 1239 or flush to lower Bollinger at 1114 before adding

• Forward P/E of 26.10 divided by 56% implied EPS growth yields 0.46 PEG ratio, but 56% growth assumes smooth integration of 8.75 billion dollar acquisition that doubled goodwill from 13.5B to 27B in one quarter
• Q2 FCF was 4.48B against 10.69B operating cash flow and 26.7B net income TTM, implying only ~40% GAAP-to-FCF conversion at 40x trailing multiple
• Foundayo regulatory approval catalyzed only 2.1% stock pop despite 90% year-to-date gains, suggesting limited incremental buyer demand at current levels
• ATR of 41.63 dollars represents 3.4% daily range, indicating elevated volatility despite 0.506 beta; 98% concentration in single name creates drawdown exposure
• August 11 candle shows buyer exhaustion signal: opened 1230.65, high 1238, low 1209.53, closed 1215.02 on below-average 1.55M shares volume
• Net debt grew 26% year-over-year; Polymarket pricing 86% probability of no rate cuts through 2026 increases discount rate risk on distant FCF recovery
• 10 EMA at 1187 and 50 SMA at 1161 provide nearer support than 200 SMA at 1035 (17% below); current price ~3 above 10 EMA leaves limited cushion
• Aggressive fair value estimate of 1214 leaves zero margin of safety at current ~1215 price level; disciplined entry target is 1115-1150

→ vs aggressive: PEG of 0.46 assumes 56% EPS growth which requires flawless Mounjaro/Zepbound ramp AND smooth integration of 8.75B acquisition; any slip in EU approval timing, competitive oral GLP-1 development, or reimbursement pressure compresses growth assumptions and doubles/triples the PEG overnight

→ vs aggressive: Foundayo 2.1% pop on regulatory approval confirms limited buyer demand at current levels; triple average volume expectations with muted price action is a market signal about incremental demand exhaustion, not just telegraphed news

→ vs aggressive: 27% capex intensity consuming more than half of Q2 operating cash flow creates 12-24 month FCF recovery horizon; elevated rates through 2026 (86% no-cut probability) increase discount rate on distant cash flows

→ vs aggressive: 0.506 beta is historical correlation that evaporates in sector-specific shock (GLP-1 safety signal, oral competitor advancement, reimbursement challenge); conditional volatility at 3.4% daily range means 80-100 dollar moves against position in single bad week

→ vs aggressive: August 11 buyer exhaustion candle at Bollinger upper band on below-average volume is textbook resistance rejection; waiting for confirmation rather than leaning in is discipline, not timidity

→ vs aggressive: 98% concentration in single name is directional bet, not conservative posture; adding capital at 1215 with zero margin of safety when fair value is 1214 turns winning year into drawdown risk

HOLD

• PEG argument is a proxy for execution confidence, not a valuation conclusion; the 0.46 PEG is mathematically correct but the inputs are aggressive assumptions
• Static 1,214 fair value math is more useful than PEG analysis as it forces the question: at what price am I compensated for execution risk?
• At 1,215, the trader is being paid essentially zero for execution risk
• Foundayo EU approval lays catalyst foundation but muted single-day reaction indicates no incremental buyer urgency at current levels
• 27% capex intensity reflects supply expansion for unconstrained demand but compresses FCF; stock is valued as if outcome is already realized
• 0.506 beta is a backward-looking historical artifact that doesn't capture forward conditional volatility for a name that has run 90% from 200 SMA with ATR of 41.63
• Absolute dollar risk per share is 41 to 83 per day on a 1,215 entry regardless of beta reading
• Technical setup: multi-week trend intact but 1,215 to 1,239 is a battleground where bulls are being tested
• Recommend tiered entry: half size at 1,150 on first test of lower Bollinger or 10 EMA, other half at 1,115 to 1,125 on flush to 50 SMA
• Trim cap at 5 to 10% of position at 1,239 rather than full exit to preserve upside to 1,275+
• 98% position concentration is the primary risk; address through portfolio construction (rotating gains into complementary healthcare or index hedge) rather than reactive LLY selling
• Macro: 86% no-cut probability is headwind for absolute multiples; hold through CPI print, use post-CPI weakness as entry trigger

→ vs aggressive: Beta argument is weaponizing a backward-looking statistic; 0.506 beta was calculated during a period when LLY was a fundamentally different investment proposition and doesn't capture forward conditional volatility at current price level with 41.63 ATR

→ vs aggressive: Trend strength doesn't mean every level resolves higher; abandoning trim discipline at 1,239 risks over-concentration but the Aggressive's framing treats this as binary upside-only risk

→ vs aggressive: The 98% concentration risk is being brushed past; regardless of direction, single-name concentration has no diversification cushion

→ vs conservative: Beta is conditional on price level but the Aggressive's relative outperformance argument in risk-off environments has merit; both beta views are partially right

→ vs conservative: Tightening add zone to sub-1.4 PEG is probably overfit to short-term caution given the multi-year compounding thesis

→ vs conservative: While FCF compression concern is valid, the Conservative underweights the timeline: if manufacturing lines come online in late 2027 with revenue acceleration, the FCF profile normalizes